Sutro Biopharma reports FY2022 revenue $67.8M, cash runway into H2 2024; plans luvelta Phase 2/3 in Q2 2023

SUTRO BIOPHARMA, INC.

Cash and investments of $302.3M plus Vaxcyte stock valued at $32.0M provide cash runway into H2 2024.
Revenue for FY2022 was $67.8M, up from $61.9M in FY2021, driven by collaboration payments.
Total operating expenses were $196.7M, up from $160.4M, with R&D at $137.2M and G&A at $59.5M.
Plans to initiate Phase 2/3 registration-directed study of luvelta in platinum-resistant ovarian cancer in Q2 2023.
Dr. Anne Borgman appointed Chief Medical Officer in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUTRO BIOPHARMA, INC. reported financial results for the full year 2022.

Period: the full year 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Sutro Biopharma, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-010978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.